Adavosertib was combined with olaparib for refractory or recurrent ovarian cancer patients with TP53 and/or KRAS mutations in a phase-II OLAPCO trial (NCT02576444) [51], based on the proposed concept that the combination of Wee1 inhibitors and TP53 loss will theoretically give coordinated efficacy, since Wee1 involves G2/M transition and p53 involves G1/S transition. Here, TP53 is linked to ovarian carcinoma.